Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 1
1948 1
1950 5
1951 4
1952 4
1953 6
1954 2
1955 3
1956 5
1957 6
1958 3
1959 13
1960 15
1961 3
1962 7
1963 7
1964 3
1965 7
1966 3
1967 11
1968 6
1969 4
1970 13
1972 3
1973 8
1974 3
1975 8
1976 5
1977 5
1978 2
1979 6
1980 12
1981 7
1982 5
1983 5
1984 2
1985 8
1986 7
1987 13
1988 7
1989 9
1990 10
1991 12
1992 12
1993 12
1994 16
1995 20
1996 18
1997 10
1998 17
1999 18
2000 19
2001 22
2002 30
2003 21
2004 34
2005 28
2006 17
2007 30
2008 39
2009 46
2010 51
2011 42
2012 59
2013 61
2014 58
2015 64
2016 55
2017 66
2018 78
2019 86
2020 98
2021 107
2022 108
2023 100
2024 99
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,630 results

Results by year

Filters applied: . Clear all
Page 1
IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation.
Faas M, Ipseiz N, Ackermann J, Culemann S, Grüneboom A, Schröder F, Rothe T, Scholtysek C, Eberhardt M, Böttcher M, Kirchner P, Stoll C, Ekici A, Fuchs M, Kunz M, Weigmann B, Wirtz S, Lang R, Hofmann J, Vera J, Voehringer D, Michelucci A, Mougiakakos D, Uderhardt S, Schett G, Krönke G. Faas M, et al. Among authors: fuchs m. Immunity. 2021 Nov 9;54(11):2531-2546.e5. doi: 10.1016/j.immuni.2021.09.010. Epub 2021 Oct 12. Immunity. 2021. PMID: 34644537 Free PMC article.
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A. Fuchs M, et al. J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10. J Clin Oncol. 2019. PMID: 31498753 Clinical Trial.
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B. Bröckelmann PJ, et al. Among authors: fuchs m. J Clin Oncol. 2023 Feb 20;41(6):1193-1199. doi: 10.1200/JCO.22.02355. Epub 2022 Dec 12. J Clin Oncol. 2023. PMID: 36508302 Clinical Trial.
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Among authors: fuchs m. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P. Eichenauer DA, et al. Among authors: fuchs m. Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10. Lancet Oncol. 2017. PMID: 29133014 Clinical Trial.
Robotics in Pediatric Urology.
Fuchs ME, DaJusta DG. Fuchs ME, et al. Int Braz J Urol. 2020 May-Jun;46(3):322-327. doi: 10.1590/S1677-5538.IBJU.2020.99.03. Int Braz J Urol. 2020. PMID: 31961623 Free PMC article. Review.
Increased Prevalence of NAFLD in IBD Patients.
Gaidos JKJ, Fuchs M. Gaidos JKJ, et al. Among authors: fuchs m. Dig Dis Sci. 2017 May;62(5):1362. doi: 10.1007/s10620-017-4552-8. Dig Dis Sci. 2017. PMID: 28357696 No abstract available.
Soluble CD83 modulates human-monocyte-derived macrophages toward alternative phenotype, function, and metabolism.
Peckert-Maier K, Wild AB, Sprißler L, Fuchs M, Beck P, Auger JP, Sinner P, Strack A, Mühl-Zürbes P, Ramadan N, Kunz M, Krönke G, Stich L, Steinkasserer A, Royzman D. Peckert-Maier K, et al. Among authors: fuchs m. Front Immunol. 2023 Dec 14;14:1293828. doi: 10.3389/fimmu.2023.1293828. eCollection 2023. Front Immunol. 2023. PMID: 38162675 Free PMC article.
Lipotoxicity in NASH.
Fuchs M, Sanyal AJ. Fuchs M, et al. J Hepatol. 2012 Jan;56(1):291-3. doi: 10.1016/j.jhep.2011.05.019. Epub 2011 Jul 8. J Hepatol. 2012. PMID: 21741924 Free article. No abstract available.
1,630 results